TriangleCRD3874-SI (NCT07661095)
CRD3874-SI trial for Relapsed or Refractory Acute Myeloid Leukemia (NCT07661095). This is a short film with English narration. The transcript is on this page, and the written brief is separate.
What the film says
Read the transcript
This trial is for adults with acute myeloid leukemia that has come back or not responded to treatment.
The idea: CRD3874-SI is a STING agonist. STING, short for stimulator of interferon genes, is an alarm switch inside cells. Turning it on may push the immune system to attack the leukemia.
The study looks at whether CRD3874-SI is safe.
This phase 1 study plans 24 patients. At Memorial Sloan Kettering Cancer Center in New York, Eytan Stein leads it.
Public record; not medical advice.
Already in a trial?
It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.
Organize my trial7-day free trial, then $9 a month. Cancel anytime.
How these trials work: what Phase 1 actually is · common questions Not clinical evidence.